Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the CIRLL Phase 1/2 Trial for CLL and MCL (Choi et al,. ASH Annual Meeting 2019)